CF
CRNX icon

Corebridge Financial’s Crinetics Pharmaceuticals CRNX Stock Holding History

Corebridge Financial’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-44,896
Closed -$1.51M – 661
2025
Q1 		$1.51M Buy
44,896
+1,297
+3% +$48.4K 0.01% 1093
2024
Q4 		$2.23M Buy
43,599
+1,992
+5% +$111K 0.01% 983
2024
Q3 		$2.13M Sell
41,607
-256
-0.6% -$13.2K 0.01% 1012
2024
Q2 		$1.88M Buy
+41,863
New +$1.93M 0.01% 1032

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Corebridge Financial's CRNX Position: Q2 2025 in Review

Corebridge Financial sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2025, closing a stake of 44,896 shares — an estimated $1.51M sold.

Corebridge Financial first reported a position in CRNX in Q2 2024 and held it in 4 quarters. The position peaked at $2.23M in Q4 2024. 222 funds tracked by Wall St. Rank hold CRNX as of Q2 2025.

  • Corebridge Financial reported no remaining Crinetics Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 44,896 Crinetics Pharmaceuticals shares in Q2 2025, an estimated $1.51M.
  • Corebridge Financial first reported a position in Crinetics Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Crinetics Pharmaceuticals position peaked at $2.23M in Q4 2024.
  • 222 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.